A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030. For context, the top 10 biopharmas in 2021 generated total global sales of $512 billion. In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs.
Protein degradation continues to be a hot area of interest for companies. Weeks after Bristol-Myers Squibb and Evotec forged a $5 billion collaboration expansion to develop molecular glue degraders, Merck KGaA and Austria’s Proxygen have struck a similar deal valued at $554 million.
Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs.
A late-stage study of two rheumatoid arthritis drugs from Bristol Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) showed a significant drop in deaths among hospitalized COVID patients, a U.S. health agency said on Thursday.
Bristol Myers Squibb (BMS) announced late-breaking data Wednesday showing that deucravacitinib, an allosteric tyrosine kinase 2 inhibitor, met the primary endpoint in the treatment of systemic lupus erythematosus.
The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.
Genentech, a member of the Roche group, announced new data on Thursday related to the company’s investigational CD20xCD3 T-cell engaging bispecific antibody glofitamab, which is intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Nearly one third of patients with ulcerative colitis who received an experimental Pfizer Inc. medicine in a clinical trial were in remission after a year of treatment, the drugmaker said on Tuesday.